AVXL
Price
$8.30
Change
-$0.25 (-2.92%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
728.15M
35 days until earnings call
TENX
Price
$6.00
Change
-$0.30 (-4.76%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
23.79M
Ad is loading...

AVXL vs TENX

Header iconAVXL vs TENX Comparison
Open Charts AVXL vs TENXBanner chart's image
Anavex Life Sciences
Price$8.30
Change-$0.25 (-2.92%)
Volume$29.23K
Capitalization728.15M
Tenax Therapeutics
Price$6.00
Change-$0.30 (-4.76%)
Volume$100
Capitalization23.79M
AVXL vs TENX Comparison Chart
Loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TENX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVXL vs. TENX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVXL is a Hold and TENX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AVXL: $8.56 vs. TENX: $6.30)
Brand notoriety: AVXL and TENX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVXL: 113% vs. TENX: 11%
Market capitalization -- AVXL: $706.46M vs. TENX: $23.79M
AVXL [@Biotechnology] is valued at $706.46M. TENX’s [@Biotechnology] market capitalization is $23.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVXL’s FA Score shows that 0 FA rating(s) are green whileTENX’s FA Score has 1 green FA rating(s).

  • AVXL’s FA Score: 0 green, 5 red.
  • TENX’s FA Score: 1 green, 4 red.
According to our system of comparison, TENX is a better buy in the long-term than AVXL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVXL’s TA Score shows that 6 TA indicator(s) are bullish while TENX’s TA Score has 4 bullish TA indicator(s).

  • AVXL’s TA Score: 6 bullish, 4 bearish.
  • TENX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AVXL is a better buy in the short-term than TENX.

Price Growth

AVXL (@Biotechnology) experienced а -8.55% price change this week, while TENX (@Biotechnology) price change was +2.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

AVXL is expected to report earnings on May 08, 2025.

TENX is expected to report earnings on Apr 03, 2023.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVXL($728M) has a higher market cap than TENX($23.8M). TENX YTD gains are higher at: 1.777 vs. AVXL (-20.298). TENX has higher annual earnings (EBITDA): -14.53M vs. AVXL (-45.2M). AVXL has more cash in the bank: 121M vs. TENX (98.3M). AVXL has less debt than TENX: AVXL (88.2K) vs TENX (279K). AVXL (0) and TENX (0) have equivalent revenues.
AVXLTENXAVXL / TENX
Capitalization728M23.8M3,059%
EBITDA-45.2M-14.53M311%
Gain YTD-20.2981.777-1,142%
P/E RatioN/AN/A-
Revenue00-
Total Cash121M98.3M123%
Total Debt88.2K279K32%
FUNDAMENTALS RATINGS
AVXL vs TENX: Fundamental Ratings
AVXL
TENX
OUTLOOK RATING
1..100
6228
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
10
Undervalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4437
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TENX's Valuation (10) in the Medical Specialties industry is somewhat better than the same rating for AVXL (61) in the Biotechnology industry. This means that TENX’s stock grew somewhat faster than AVXL’s over the last 12 months.

AVXL's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as TENX (100) in the Medical Specialties industry. This means that AVXL’s stock grew similarly to TENX’s over the last 12 months.

TENX's SMR Rating (96) in the Medical Specialties industry is in the same range as AVXL (97) in the Biotechnology industry. This means that TENX’s stock grew similarly to AVXL’s over the last 12 months.

TENX's Price Growth Rating (37) in the Medical Specialties industry is in the same range as AVXL (44) in the Biotechnology industry. This means that TENX’s stock grew similarly to AVXL’s over the last 12 months.

TENX's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as AVXL (100) in the Biotechnology industry. This means that TENX’s stock grew similarly to AVXL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVXLTENX
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TENX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCGMX19.000.10
+0.53%
NYLI PineStone Global Equity Class R6
BAICX10.180.02
+0.20%
BlackRock Multi-Asset Income Investor A
MICYX8.43N/A
N/A
Victory Trivalent Intl Fd-Core Eq Y
PJERX14.09N/A
N/A
PGIM Jennison Global Equity Income R
USLYX65.66N/A
N/A
JHancock U.S. Global Leaders Growth R2